Please enable JavaScript.
Coggle requires JavaScript to display documents.
kanamycin (moa (Kanamycin binds to four nucleotides of 16S rRNA and a…
kanamycin
moa
-
This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA.
-
This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
Pharmacodynamics
aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter
Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host
Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth
Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
Pharmacokinetics
absorption
-
rapidly absorbed after intramuscular injection and peak serum levels are generally reached within approximately one hour
distribution
distributed into most body tissues and fluids,1 including pleural fluid, peritoneal fluid, synovial fluid, ascitic fluid, gallbladder, and bile
-
Adverse drug reaction
Ototoxicity, Skin rash, headache, nausea, vomiting, diarrhoea.
-
-
clinical use
For treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species
-